Lisanti Capital Growth LLC Boosts Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL)

Lisanti Capital Growth LLC lifted its stake in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 60.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 154,710 shares of the company's stock after purchasing an additional 58,160 shares during the quarter. Lisanti Capital Growth LLC owned 0.56% of Castle Biosciences worth $4,412,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Principal Financial Group Inc. grew its holdings in shares of Castle Biosciences by 2.7% during the third quarter. Principal Financial Group Inc. now owns 1,538,520 shares of the company's stock valued at $43,879,000 after buying an additional 40,377 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Castle Biosciences by 2.2% during the first quarter. Vanguard Group Inc. now owns 1,494,176 shares of the company's stock valued at $33,096,000 after purchasing an additional 32,695 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Castle Biosciences by 8.1% during the second quarter. Dimensional Fund Advisors LP now owns 809,934 shares of the company's stock valued at $17,631,000 after buying an additional 60,675 shares during the last quarter. Renaissance Technologies LLC increased its holdings in Castle Biosciences by 47.3% in the 2nd quarter. Renaissance Technologies LLC now owns 301,500 shares of the company's stock worth $6,564,000 after buying an additional 96,800 shares in the last quarter. Finally, Acadian Asset Management LLC raised its position in Castle Biosciences by 33.0% in the 2nd quarter. Acadian Asset Management LLC now owns 280,497 shares of the company's stock worth $6,101,000 after buying an additional 69,673 shares during the last quarter. Institutional investors own 92.60% of the company's stock.

Wall Street Analyst Weigh In

CSTL has been the subject of several research analyst reports. Scotiabank lifted their price objective on Castle Biosciences from $37.00 to $44.00 and gave the stock a "sector outperform" rating in a report on Wednesday, November 6th. Lake Street Capital upped their price target on shares of Castle Biosciences from $34.00 to $40.00 and gave the company a "buy" rating in a research report on Tuesday, November 5th. Robert W. Baird boosted their price target on Castle Biosciences from $37.00 to $39.00 and gave the company an "outperform" rating in a report on Tuesday, November 5th. BTIG Research raised their price objective on shares of Castle Biosciences from $35.00 to $40.00 and gave the company a "buy" rating in a research report on Monday, October 14th. Finally, Canaccord Genuity Group increased their price objective on shares of Castle Biosciences from $35.00 to $42.00 and gave the company a "buy" rating in a report on Tuesday, October 29th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, Castle Biosciences has an average rating of "Buy" and a consensus target price of $37.88.

Insiders Place Their Bets

In other news, insider Tobin W. Juvenal sold 3,507 shares of Castle Biosciences stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $35.56, for a total transaction of $124,708.92. Following the completion of the sale, the insider now directly owns 54,178 shares in the company, valued at approximately $1,926,569.68. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Castle Biosciences news, insider Tobin W. Juvenal sold 3,507 shares of the business's stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $35.56, for a total transaction of $124,708.92. Following the completion of the sale, the insider now directly owns 54,178 shares in the company, valued at approximately $1,926,569.68. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Derek J. Maetzold sold 986 shares of Castle Biosciences stock in a transaction that occurred on Friday, October 4th. The stock was sold at an average price of $28.73, for a total value of $28,327.78. Following the completion of the sale, the insider now directly owns 94,622 shares in the company, valued at $2,718,490.06. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 15,318 shares of company stock worth $478,124 over the last 90 days. Company insiders own 7.20% of the company's stock.

Castle Biosciences Trading Up 1.3 %

Shares of NASDAQ:CSTL traded up $0.43 during trading on Monday, hitting $33.72. The company had a trading volume of 227,389 shares, compared to its average volume of 324,544. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.78 and a quick ratio of 7.92. The company has a fifty day simple moving average of $30.92 and a two-hundred day simple moving average of $25.95. The stock has a market cap of $944.50 million, a price-to-earnings ratio of 169.26 and a beta of 0.99. Castle Biosciences, Inc. has a one year low of $16.51 and a one year high of $35.84.

Castle Biosciences (NASDAQ:CSTL - Get Free Report) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.08 EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.14. The firm had revenue of $85.78 million for the quarter, compared to analysts' expectations of $78.55 million. Castle Biosciences had a net margin of 1.95% and a return on equity of 1.47%. During the same period in the prior year, the business posted ($0.26) earnings per share. As a group, equities analysts forecast that Castle Biosciences, Inc. will post -0.08 earnings per share for the current year.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.